@article{be80a90c0fd444a3a1cfea67e1fe68b1,
title = "Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals",
abstract = "Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings. ",
keywords = "hepatitis C, antiviral treatment, intravenous drug users",
author = "Martin, {Natasha K.} and Peter Vickerman and Jason Grebely and Margaret Hellard and Hutchinson, {Sharon J.} and Lima, {Viviane D.} and Foster, {Graham R.} and Dillon, {John F.} and Goldberg, {David J.} and Dore, {Gregory J.} and Matthew Hickman",
note = "Copyright VC 2013 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. View this article online at wileyonlinelibrary.com. DOI 10.1002/hep.26431",
year = "2013",
month = nov,
doi = "10.1002/hep.26431",
language = "English",
volume = "58",
pages = "1598–1609",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",
}